title: Fibrates for treatment of the metabolic syndrome.
abstract: The National Cholesterol Education Program Adult Treatment Panel III has provided a clinical definition for the metabolic syndrome that is practical for use in an office setting. Identification and treatment of the metabolic syndrome is of enormous public health importance because it is associated with a marked elevation in coronary heart disease risk and affects nearly 25% of adults in the United States. First-line therapy is lifestyle modification, which includes body weight reduction, increased physical activity, and moderation of the dietary glycemic load. Drug treatments focusing on the major components of the syndrome (atherogenic dyslipidemia, hypertension, and a prothrombotic state) have demonstrated efficacy for reducing coronary heart disease events. Fibrates seem to be particularly effective in patients for whom a disturbance of the triglyceride-high-density lipoprotein axis is the primary lipid disorder. Fibrates also appear to influence a number of emerging risk factors, including hemostatic and inflammatory markers and indicators of improved vascular wall biology, which may contribute to their cardioprotective effects.
authors.affiliation: Radiant Research, 515 North State Street, Suite 2700, Chicago, IL 60610, USA. kevinmaki@radiantresearch.com
authors.forename: Kevin C
authors.initials: KC
authors.lastname: Maki
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control; D002986:Clinical Trials as Topic; D002994:Clofibrate / Q000627:therapeutic use; D011345:Fenofibrate / Q000627:therapeutic use; D015248:Gemfibrozil / Q000627:therapeutic use; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D015995:Prevalence
chemical_list: D000960:Hypolipidemic Agents; D002994:Clofibrate; D015248:Gemfibrozil; D011345:Fenofibrate